In a recent transaction, Steven Leonard, the CEO and President of Natera, Inc. (NASDAQ:), a leader in personalized genetic testing and diagnostics, sold a notable amount of company stock. On September 16, Leonard parted with shares in a series of transactions that resulted in a total sale value exceeding $645,000.
The sale consisted of multiple blocks of shares sold at varying prices, with the weighted average prices ranging from $126.6641 to $130.932 per share. Specifically, the transactions were executed in price ranges as follows: some shares were sold between $126.35 and $126.8350, others between $127.41 and $128.40, a further set between $128.46 and $129.44, additional shares between $129.64 and $130.3450, and the final batch between $130.83 and $131.18. These sales were conducted under a Rule 10b5-1 trading plan, which was adopted by Leonard on December 11, 2023.
The shares sold by Leonard represent a decrease in his direct ownership of Natera stock, although the exact percentage of his remaining stake was not disclosed in the filing. After these transactions, Leonard still holds a significant number of shares, indicating continued vested interest in the company’s performance.
Investors often monitor insider sales as they can provide insights into the executives’ perspectives on the company’s current valuation and future prospects. However, it’s important to note that insider transactions can be subject to various personal financial strategies and do not necessarily signal changes in company fundamentals.
Natera has been at the forefront of genetic testing, offering a range of services that include prenatal screening, cancer risk assessment, and organ transplant monitoring. The company’s commitment to advancing health care through genetic testing continues to be a focal point of its business strategy.
The details of these transactions are publicly available in the latest SEC filings, providing transparency to investors and the broader market.
In other recent news, Natera Inc . has seen a surge in revenue and growth, reporting a 12% sequential revenue increase from the first quarter and a 58% year-over-year increase. The company has raised its full-year revenue guidance to approximately $1.5 billion, with a gross margin expectation of 55%. These developments come alongside a record number of test volumes and a rise in average selling prices.
In anticipation of the new Galaxy study results, Piper Sandler maintains a positive stance on Natera, reiterating an Overweight rating and a price target of $150.00. The firm acknowledges Natera’s significant lead in the market, particularly with its cancer test, Signatera.
TD Cowen and Canaccord Genuity also maintained their Buy ratings on Natera shares, expressing optimism for the company’s prospects following presentations at the European Society for Medical Oncology conference. Notably, Natera’s Renasight test has received an endorsement from the National Kidney Foundation for chronic kidney disease testing.
These are some of the recent developments that highlight Natera’s strong market position and potential for continued growth.
InvestingPro Insights
Natera, Inc. (NASDAQ:NTRA) has shown significant market activity, capturing investor attention with its notable performance metrics. According to InvestingPro data, Natera boasts a market capitalization of $15.74 billion, reflecting its substantial presence in the genetic testing industry. Despite the lack of profitability in the last twelve months, with a P/E ratio of -52.52, the company’s revenue growth has been impressive, with a 46.13% increase in the last twelve months as of Q2 2024. This growth trend is further evidenced by a quarterly revenue growth of 58.13% in Q2 2024, highlighting the company’s expanding market reach and operational scale.
InvestingPro Tips highlight that Natera’s stock price movements have been quite volatile, which could be significant for investors looking for short-term trading opportunities or those concerned about market stability. Additionally, while analysts have revised their earnings upwards for the upcoming period, they do not anticipate the company will be profitable this year. This juxtaposition of high revenue growth against a backdrop of anticipated non-profitability could signal an investment that is more speculative in nature, with potential for future growth.
For investors seeking more detailed analysis and additional InvestingPro Tips, Natera currently has 14 listed on InvestingPro, including insights on stock price trends, liquidity, and debt levels. These tips can provide a deeper understanding of the company’s financial health and market position, accessible at https://www.investing.com/pro/NTRA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
